Crinetics Pharmaceuticals, Inc.
CRNXNASDAQHealthcare● Active
$33.48
+$0.56(+1.70%)
Market Cap$3.5B
P/E Ratio—
52W High$57.99
52W Low$25.83
Crinetics Pharmaceuticals, Inc. (CRNX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CRNX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $7.70M | $1.04M | $4.01M | $4.74M | $1.08M |
| Cost of Revenue | $1.08M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $6.62M | $1.04M | $4.01M | $4.74M | $1.08M |
| Gross Margin %(computed) | 86.02% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $332.06M | $240.16M | $168.53M | $130.22M | $84.25M |
| G&A Expenses | $191.33M | $99.74M | $58.09M | $42.39M | $24.52M |
| Total Operating Expenses | $523.39M | $339.89M | $226.62M | $172.62M | $108.78M |
| Operating Income | ($516.77M) | ($338.85M) | ($222.61M) | ($167.88M) | ($107.70M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $51.99M | $41.44M | $13.44M | $4.32M | $0.16M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($465.14M) | ($298.41M) | ($214.53M) | ($163.92M) | ($107.64M) |
| Income Tax Expense | $0.18M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($465.32M) | ($298.41M) | ($214.53M) | ($163.92M) | ($107.64M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
| Wtd Avg Shares | 94.06M | 80.78M | 58.07M | 51.98M | 38.44M |
| EBITDA | ($512.88M) | ($336.07M) | ($221.51M) | ($166.90M) | ($106.78M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Crinetics Pharmaceuticals, Inc. data
About Crinetics Pharmaceuticals, Inc. (CRNX) Income Statement
Crinetics Pharmaceuticals, Inc. (CRNX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CRNX reported revenue of $0.01B, gross profit of $0.01B (gross margin 86.02%), and net income of ($0.47B) — a net profit margin of -6046.22%.
Frequently asked questions
CRNX · 4 questionsCrinetics Pharmaceuticals, Inc. (CRNX) reported revenue of $0.01B for 2025, up 640.7% year-over-year.
CRNX revenueCRNX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08